Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
South Africa
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Epoprostanol
2. Epoprostenol
3. Epoprostenol Sodium Salt, (5z,9alpha,11alpha,13e,15s)-isomer
4. Flolan
5. Prostacyclin
6. Prostaglandin I(2)
7. Prostaglandin I2
8. Veletri
1. Flolan
2. Epoprostenol
3. Prostacyclin Sodium Salt
4. 61849-14-7
5. Sodium Prostacyclin
6. Prostaglandin I2
7. U-53217a
8. U-53,217a
9. 4k04iq1of4
10. Cyclo-prostin
11. 35121-78-9
12. Epoprostenol Sodium [usan:ban]
13. Ncgc00167427-01
14. Einecs 263-273-7
15. Unii-4k04iq1of4
16. Floran
17. U 53,217a
18. Epoprostenolsodium
19. Prostacyclin Sodium
20. Prostaglandin X Sodium
21. Prostaglandin I2 Na
22. Chembl962
23. Dsstox_cid_26617
24. Dsstox_rid_81769
25. Sodium (5z,13e,15s)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate
26. Dsstox_gsid_46617
27. Schembl41344
28. Sodium (z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-delta(sup 2,delta)-valerate
29. Bml1-f10
30. Dtxsid3046617
31. Epoprostenol Sodium [jan]
32. 4ua76
33. Epoprostenol Sodium [usan]
34. Hms1361k18
35. Hms3648l14
36. Epoprostenol Sodium [vandf]
37. Epoprostenol Sodium [mart.]
38. Tox21_112431
39. Epoprostenol Sodium [usp-rs]
40. Epoprostenol Sodium [who-dd]
41. Prostacyclin Sodium Salt [mi]
42. Akos024457370
43. Epoprostenol Sodium [orange Book]
44. Prosta-5,13-dien-1-oic Acid, 6,9-epoxy-11,15-dihydroxy-, Sodium Salt, (5z,9alpha,11alpha,13e,15s)-
45. Cas-61849-14-7
46. Q27259818
47. (5z,13e,8r,9s,11r,12r,15s)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic Acid Sodium Salt
48. Prosta-5,13-dien-1-oic Acid, 6,9-epoxy-11,15-dihydroxy-, Sodium Salt, (5z,9.alpha.,11.alpha.,13e,15s)-
49. Sodium (z)-(3ar,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s)-3-hydroxy-1-octenyl)-2h-cyclopenta(b)furan-.delta.(sup 2,.delta.)-valerate
50. Sodium (z)-5-((3ar,4r,5r,6as)-5-hydroxy-4-((s,e)-3-hydroxyoct-1-enyl)hexahydro-2h-cyclopenta[b]furan-2-ylidene)pentanoate
Molecular Weight | 374.4 g/mol |
---|---|
Molecular Formula | C20H31NaO5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 10 |
Exact Mass | 374.20691837 g/mol |
Monoisotopic Mass | 374.20691837 g/mol |
Topological Polar Surface Area | 89.8 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 491 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Epoprostenol sodium |
PubMed Health | Epoprostenol (Injection) |
Drug Classes | Peripheral Vasodilator, Platelet Aggregation Inhibitor |
Drug Label | Epoprostenol sodium for injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of epoprostenol sodium for injection contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) e... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Teva Pharms Usa |
2 of 4 | |
---|---|
Drug Name | Flolan |
Drug Label | FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5mg (500,000ng) or 1.5mg (1,500,000ng) epoprostenol, 3... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Glaxosmithkline |
3 of 4 | |
---|---|
Drug Name | Epoprostenol sodium |
PubMed Health | Epoprostenol (Injection) |
Drug Classes | Peripheral Vasodilator, Platelet Aggregation Inhibitor |
Drug Label | Epoprostenol sodium for injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of epoprostenol sodium for injection contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) e... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Teva Pharms Usa |
4 of 4 | |
---|---|
Drug Name | Flolan |
Drug Label | FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5mg (500,000ng) or 1.5mg (1,500,000ng) epoprostenol, 3... |
Active Ingredient | Epoprostenol sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 1.5mg base/vial; eq 0.5mg base/vial |
Market Status | Prescription |
Company | Glaxosmithkline |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC09 - Epoprostenol
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-27
Pay. Date : 2019-09-13
DMF Number : 21584
Submission : 2008-04-28
Status : Active
Type : II
Registration Number : 221MF10112
Registrant's Address : ul. Pra(´)ce 657,277 11 Neratovice, Czech Republic
Initial Date of Registration : 2009-06-10
Latest Date of Registration : --
NDC Package Code : 61556-030
Start Marketing Date : 2011-04-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA, AU, ASMF |
NDC Package Code : 68245-0005
Start Marketing Date : 2005-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19539
Submission : 2006-06-22
Status : Active
Type : II
NDC Package Code : 82231-106
Start Marketing Date : 2014-10-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, ROW |
Registration Number : 221MF10006
Registrant's Address : 4OC Commercial Park Little Island Cork, Ireland
Initial Date of Registration : 2009-01-13
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19971
Submission : 2006-11-15
Status : Active
Type : II
Date of Issue : 2022-07-26
Valid Till : 2025-07-14
Written Confirmation Number : WC-0130
Address of the Firm :
NDC Package Code : 14474-025
Start Marketing Date : 2012-10-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-03-06
Pay. Date : 2016-02-23
DMF Number : 30263
Submission : 2017-01-07
Status : Active
Type : II
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm :
NDC Package Code : 62756-033
Start Marketing Date : 2021-01-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-26
Pay. Date : 2023-08-29
DMF Number : 27420
Submission : 2013-08-24
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0004
Start Marketing Date : 2011-09-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6065
Submission : 1985-10-16
Status : Active
Type : II
Registration Number : 218MF10929
Registrant's Address : 7000 Portage Road, Kalamazoo, Michigan 49001, USA
Initial Date of Registration : 2006-11-21
Latest Date of Registration : --
NDC Package Code : 0009-5164
Start Marketing Date : 2014-07-03
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21311
Submission : 2008-02-05
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?